

# **Clinical Observation of 79 Cases of Allergic Skin Diseases Treated with BICOM2000 Bio-Resonance Device**

By Yang Jinzhi

The Department of Allergy of Jinan Children's Hospital

**Abstract:** This article aims to show the clinical observation of 79 cases of allergic skin diseases treated with BICOM2000 bio-resonance device. After we conducted the allergen tests and desensitization treatment, the total effectiveness rate is 89.9% and recovery rate is 74.7%.

**Key Words:** Bio-Resonance Therapy; Allergic Skin Diseases; Desensitization

In May 2003, our hospital led the country in introducing the BICOM2000 from Germany, and applied it for clinical treatment. We conducted allergen tests and desensitization treatment to 79 patients who suffer from allergic skin diseases. Hereunder is our clinical observation and reports:

## **I. Sources and Method:**

### 1. Selection of Cases:

All 79 cases are from patients of our hospital, of which 31 are males and 48 females; 12 adults and 57 children; The age ranges from 3 months old to 74 years old; The course of diseases lasts from 3 days to 21 years. All these cases involve 27 baby eczema-sufferers, 32 urticaria-sufferers and 20 atopic-dermatitis (AD) sufferers. The BICOM2000 bi-resonance therapy is conducted 7-10 days after stopping using anti-allergy medicines and hormones.

### 2. Methods:

(1). Allergen Test: Taking advantages of the 491 sample allergens of the BICOM2000, through infrared receiver, we conduct tests on 20 acupuncture points of the sufferer's fingers of both hands. In the cases of baby sufferers under 3 years old, who can't cooperate with doctors, we take the mother's milk of the baby as the allergen. We try to get a more correct inferences based on the details of life and food provided by the parents, or we try to find out the allergen with other testing method.

Under special circumstances, we ask the patient to bring us the suspected allergens.

(2). Desensitization Therapy: 79 sufferers are conducted desensitization with the BICOM2000 bio-resonance device. We put a little amount of saliva or a drop of blood (or 1mm urine of baby eczema-sufferer) into the information cup. We conduct basic treatment and follow-up treatment before we put the sample allergen into the information cup for desensitization. Each time we desensitize 2 or 3 main allergens for 6-30 minutes (it depends on the sufferers' ages), once a week. If the patients are under serious conditions and in the breaking-out period, the desensitization can be made once per 3 days. Most sufferers need 6-9 times of desensitization before the symptoms of allergic skin diseases disappear. The treatment will stop when the allergens are re-examined as negatives.

### 3. The Standard for Judging the Curative Effect:

We judge the curative effect based on the disappearances of rash and the recurrences within half a year after treatment. Recovery: Rash disappears totally. No recurrences happen when contacting with allergens; Obviously Effective: Rash disappears totally. Slight recurrences happen when the sufferer contacts allergens 3 months later; Effective: The number of rashes decreases, and rash becomes smaller, and the skin itch alleviates; Ineffective: Rash slightly improves than before, or recurrences happen before the end of the course of treatment. The effectiveness rate includes recovery rate and obvious effectiveness rate.

II. Clinical Results: Please see the table.

### **Clinical Results and Evaluation about 79 Cases of Allergic Skin Diseases Treated with BICOM2000**

Name of Diseases	Cases	Recovery	Obviously Effective	Effective	Ineffective
Eczema	27	21	4	2	0
Urticaria	32	26	5	1	0
Atopic-Dermatitis	20	12	3	3	2
Total	79	63	12	6	2
%		74.7%	5.2%	7.6%	2.5%

We treat 79 allergic-rash sufferers with the BICOM2000 bio-resonance device, with a recovery rate of 74.7% and an effectiveness rate of 89.9%. All patients do not show any unhealthy signs during the course of treatment, only few of them feel a little bit tiredness. Some baby sufferers improve appetite and feel smooth in relieving themselves.

### III. Discussion

The application of the bio-resonance treatment technology to clinical practices is based on the theory of quantum physical wave proposed by the French scientist, Mr. Louis Victor De Broglie. This theory holds that each substance has its own specific wave pattern. When a certain allergen contacts the human body, it will stimulate human body to generate a mark in the body, which can be regarded as an abnormal wave pattern. When human body contacts the allergen again, it will generate a stronger electromagnetic vibrant wave (The mark is activated). The disturbed electromagnetic vibrant wave can be obtained from an electrode attached to human body, and put into the BICOM2000 device. After these wave patterns are reversed and magnified within the device, the reversed vibrant waves can be returned back to the sufferer's body in a way of vibrant waves for treatment to readjust the remained electromagnetic vibrant waves into normal ones (The mark is erased). Thus, the human body will be restored in this way. I am involved in the treatment of the 79 cases of the allergic skin diseases with the BICOM2000 bio-resonance device. The recovery rate reaches 74.9% and effectiveness rate 89.9%. All patients have not shown unhealthy signs during the treatments. With the remarkable curative effect, the BICOM2000 is especially effective to baby eczema sufferers. This device has a much wider range of sample allergens, ensuring the allergen test more accurate and more extensively applicable. Without pain, hurt and side-effect during treatment process, it is easy to be accepted by patients especially children sufferers. It not only shortens the treatment time, but also brings curative effect in a short time. Thus, it can be used to replace the allergen test and treatment method that we used before. It is also worth further popularizing. However, we need more time to further observe its long-term curative effect.

## Bibliography:

- (1). prf.b.Schneider,HanoverMdical:erfahrungsheilkunde11/1994
- (2). 宋克敏等百康生物共振治疗系统治疗变态反应性疾病临床疗效观察,临床皮肤科杂志 2003, 32 (10:) 616-617